CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
cabergolinedrug
Likely dose
cabergoline 1.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01014793
NCT01014793N/ACompleted
CompareCT.gov

Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly

Federal University of São Paulo·observational·Posted Nov 17, 2009·Updated Nov 17, 2009

In Brief

An observational study evaluating cabergoline for Acromegaly. Completed, enrolled 19 participants across 1 site.

Detailed Summary

In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 17, 2009
Enrollment StartMay 1, 2005
Primary CompletionMay 1, 2007
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.6 years ago

Interventions

cabergolinedrug

cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal